

Special Issue

Antibiotics: Reconciling Profit and Sustainable Use

Message from the Guest Editor

New antibiotics must become a profitable venture for industry if we are to get the new products that we need. However, if we continue to allow sales volumes to directly determine company profits, we should expect continued overuse of these valuable resources and the shorter duration of efficacy that comes with it. Incentives for stimulating the R&D of new antibiotics are a hot topic right now. Many incentive designs are being put on the table. Some detangle the perverse incentive to maximize sales volumes but others do not. This Special Issue discusses the progress that has been made in this area over the past few years, including from the pilot schemes that have been launched, and in light of the COVID-19 pandemic. Crucially, it also considers the political level to assess how change can be best achieved and where movement is needed next, considering the implications of geographic scope.

Guest Editor

Dr. Chantal M. Morel

Faculty of Medicine, University of Geneva, Rue Michel-Servet 1, 1206 Geneva, Switzerland

Deadline for manuscript submissions

closed (30 November 2021)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/65629

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)